ThromboGenics' microplasmin meets Phase III trial for "back of the eye" diseases
This article was originally published in Scrip
Executive Summary
ThromboGenics' microplasmin has met primary endpoint and secondary endpoints for the non-surgical treatment of vitreomacular adhesion (VMA), show pivotal trial data presented at the World Ophthalmology Congress in Berlin. The Belgian company's share price was up just over 5% on the news, to €16.95 ($20.44), on the Brussels stock exchange.